

Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Defin.	Errors
1	BRS	L1	chi-conotoxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:32			0
2	BRS	L2	neuronal adj amine adj transporter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:32			0
3	BRS	L3	neuronal adj noradrenaline adj transporter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:33			0
4	BRS	L4	chi-mria or chi-mrib	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:33			0
5	BRS	L5	conotoxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:34			0
6	BRS	L6	conotoxin same ((neuronal adj amine adj transporter) or (neuronal adj noradrenaline adj transporter))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:34			0
7	BRS	L7	chimeric same 1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:34			0
8	BRS	L8	(urinary or fecal) adj incontinence	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:35			0
9	BRS	L9	(cardiovascular adj disease) or arrhythmia or (coronary adj heart adj failure) or (mood adj disorder) or depression or anxiety or cravings or (chronic adj pain) or (neuropathic adj pain) or (inflammatory adj pain)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:35			0

Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Defin	Errors
10	BRS	L10 1	((cardiovascular adj disease) or arrhythmia or (coronary adj heart adj failure) or (mood adj disorder) or depression or anxiety or cravings or (chronic adj pain) or (neuropathic adj pain) or (inflammatory adj pain)) same (chi-conotoxin or (conotoxin same ((neuronal adj amine adj transporter) or (neuronal adj noradrenaline adj transporter))))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:37			0
11	BRS	L11 343	lewis adj richard.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:41			0
12	BRS	L12 2	alewood adj paul.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:40			0
13	BRS	L13 0	sharpe adj iain.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:42			0
14	BRS	L15 0	(l1 or 12) and 1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:39			0
15	BRS	L17 4	alewood adj p adj f.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:40			0
16	BRS	L18 31	lewis adj r adj j.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:41			0
17	BRS	L19 2	sharpe adj i adj a.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:42			0
18	BRS	L20 1	(l7 or 18 or 19) and 1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/08/29 08:42			0

FILE 'MEDLINE' ENTERED AT 08:46:04 ON 29 AUG 2003

FILE 'CAPLUS' ENTERED AT 08:46:04 ON 29 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:46:04 ON 29 AUG 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 08:46:04 ON 29 AUG 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 08:46:04 ON 29 AUG 2003

COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 08:46:04 ON 29 AUG 2003

=> s chi-conotoxin
L1 2 CHI-CONOTOXIN

=> duplicate remove l1

DUPPLICATE PREFERENCE IS 'CAPLUS, EMBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L1

L2 2 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> d 12 1-2 ibib abs

L2 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2001134193 EMBASE

TITLE: Composition and therapeutic utility of conotoxins from
genus Conus. Patent status 1996 - 2000.

AUTHOR: Jones R.M.; Cartier G.E.; McIntosh J.M.; Bulaj G.; Farrar
V.E.; Olivera B.M.

CORPORATE SOURCE: R.M. Jones, Cognetix Inc., 421 Wakara Way, Salt Lake City,
UT 84108, United States. rjones@cognetix.com

SOURCE: Expert Opinion on Therapeutic Patents, (2001) 11/4
(603-623).

Refs: 51

ISSN: 1354-3776 CODEN: EOTPEG

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 008 Neurology and Neurosurgery
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

AB With an exponentially increasing body of scientific evidence pointing
toward the potential of conotoxins for treatment of a wide variety of
nervous system and associated neurological disorders, there has been an
explosion of activity in this patent area with more than eighty new
patents and PCT publications in the past five years. With the emergence of
ziconotide (SNX-111, .omega.-conotoxin MVIIA) as the first clinically used
conotoxin for treatment of a neurological disorder, the first part of the
new millennium is likely to see many more new filings in this field. The
majority of the applications from this period focus on those classes of
conopeptides that interact with nicotinic acetylcholine receptors (nAChRs)
together with those that block voltage-gated ion channels. This arena has
to date been dominated by three research groups: Neurex (a wholly-owned
subsidiary of Elan, South San Francisco, CA, USA), Xenome and the
Institute for Molecular Bioscience (IMB), University of Queensland
(Melbourne, Australia) and Cognetix (Salt Lake City, UT, USA) together
with the University of Utah Research Foundation and the Salk Institute for
Biological Studies (La Jolla, CA, USA).

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:241270 CAPLUS

DOCUMENT NUMBER: 132:288779

TITLE: Recombinant . ***chi*** .- ***conotoxin***

peptides for inhibiting neuronal amine transporters

INVENTOR(S): Lewis, Richard James; Alewood, Paul Francis; Sharpe,
Iain Andrew

PATENT ASSIGNEE(S): The University of Queensland, Australia
SOURCE: PCT Int. 11, 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020444	A1	20000413	WO 1999-AU844	19991001
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344765	AA	20000413	CA 1999-2344765	19991001
AU 9964530	A1	20000426	AU 1999-64530	19991001
AU 757011	B2	20030130		
EP 1117682	A1	20010725	EP 1999-952156	19991001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526098	T2	20020820	JP 2000-574555	19991001

PRIORITY APPLN. INFO.: AU 1998-6274 A 19981002
WO 1999-AU844 W 19991001

AB The invention relates to an isolated, synthetic or recombinant <<
chi - ***conotoxin*** peptide having the ability to inhibit a
neuronal amine transporter, nucleic acid mols. encoding all or part of
such peptides, antibodies to such peptides and uses and methods of
treatment involving them.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s neuronal amine transporter
L3 2 NEURONAL AMINE TRANSPORTER

=> s neuronal noradrenaline transporter
L4 41 NEURONAL NORADRENALINE TRANSPORTER

=> s l3 or l4
L5 43 L3 OR L4

=> d his

(FILE 'HOME' ENTERED AT 08:45:42 ON 29 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
08:46:04 ON 29 AUG 2003

L1 2 S CHI-CONOTOXIN
L2 2 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)
L3 2 S NEURONAL AMINE TRANSPORTER
L4 41 S NEURONAL NORADRENALINE TRANSPORTER
L5 43 S L3 OR L4

=> s l5 (p) l1
L6 1 L5 (P) L1

=> s l6 not l2
L7 0 L6 NOT L2

=> s chi-mria or chi-mrib
L8 4 CHI-MRIA OR CHI-MRIB

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L8
L9 1 DUPLICATE REMOVE L8 (3 DUPLICATES REMOVED)

=> s l9 not l1
L10 1 L9 NOT L1

=> d l10 1 ibib abs

L10 ANSWER 1 OF 1 MEDLINE on STN
ACCESSION NUMBER: 2001486070 MEDLINE
DOCUMENT NUMBER: 21419681 PubMed ID: 11528421
TITLE: Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter.
AUTHOR: Sharpe I A; Gehrmann J; Loughnan M L; Thomas L; Adams D A; Atkins A; Palant E; Craik D J; Adams D J; Alewood P F; Lewis R J
CORPORATE SOURCE: Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia.
SOURCE: NATURE NEUROSCIENCE, (2001 Sep) 4 (9) 902-7.
Journal code: 9809671. ISSN: 1097-6256.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: PDB-1IEN; PDB-1IEO
ENTRY MONTH: 200109
ENTRY DATE: Entered STN: 20010903
Last Updated on STN: 20010924
Entered Medline: 20010920

AB Cone snails use venom containing a cocktail of peptides ('conopeptides') to capture their prey. Many of these peptides also target mammalian receptors, often with exquisite selectivity. Here we report the discovery of two new classes of conopeptides. One class targets alpha1-adrenoceptors (rho-TIA from the fish-hunting *Conus tulipa*), and the second class targets the neuronal noradrenaline transporter (***chi*** - ***MRIA*** and ***chi*** - ***MrIB*** from the mollusk-hunting *C. marmoreus*). rho-TIA and ***chi*** - ***MrIA*** selectively modulate these important membrane-bound proteins. Both peptides act as reversible non-competitive inhibitors and provide alternative avenues for the identification of inhibitor drugs.

=> s (urinary or fecal) (w) incontinence

L11 43501 (URINARY OR FECAL) (W) INCONTINENCE

=> s (cardiovascular disease) OR arrhythmia or (coronary heart failure) or (mood disorder) or depre
4 FILES SEARCHED...

L12 1109450 (CARDIOVASCULAR DISEASE) OR ARRHYTHMIA OR (CORNARY HEART FAILURE) OR (MOOD DISORDER) OR DEPRESSION OR ANXIETY OR CRAVINGS OR (CHRONIC PAIN) OR (NEUROPATHIC PAIN) OR (INFLAMMATORY PAIN)

=> d his

(FILE 'HOME' ENTERED AT 08:45:42 ON 29 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 08:46:04 ON 29 AUG 2003

L1 2 S CHI-CONOTOXIN
L2 2 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)
L3 2 S NEURONAL AMINE TRANSPORTER
L4 41 S NEURONAL NORADRENALINE TRANSPORTER
L5 43 S L3 OR L4
L6 1 S L5 (P) L1
L7 0 S L6 NOT L2
L8 4 S CHI-MRIA OR CHI-MRIB
L9 1 DUPLICATE REMOVE L8 (3 DUPLICATES REMOVED)
L10 1 S L9 NOT L1
L11 43501 S (URINARY OR FECAL) (W) INCONTINENCE
L12 1109450 S (CARDIOVASCULAR DISEASE) OR ARRHYTHMIA OR (CORNARY HEART FAIL

=> s l12 (p) l1
L13 0 L12 (P) L1

=> s lewis richard/au
L14 74 LEWIS RICHARD/AU

=> s alewood paul/au
L15 27 ALEWOOD PAUL/AU

=> s sharpe iain/au
L16 1 SHARPE IAIN/AU

=> s (l14 or l15 or l16) and l1

L17 0 (L14 OR L15 OR L16) AND L1

=>
=> d his

(FILE 'HOME' ENTERED AT 08:45:42 ON 29 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
08:46:04 ON 29 AUG 2003

L1 2 S CHI-CONOTOXIN
L2 2 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)
L3 2 S NEURONAL AMINE TRANSPORTER
L4 41 S NEURONAL NORADRENALINE TRANSPORTER
L5 43 S L3 OR L4
L6 1 S L5 (P) L1
L7 0 S L6 NOT L2
L8 4 S CHI-MRIA OR CHI-MRIB
L9 1 DUPLICATE REMOVE L8 (3 DUPLICATES REMOVED)
L10 1 S L9 NOT L1
L11 43501 S (URINARY OR FECAL) (W) INCONTINENCE
L12 1109450 S (CARDIOVASCULAR DISEASE) OR ARRHYTHMIA OR (CORNARY HEART FAIL
L13 0 S L12 (P) L1
L14 74 S LEWIS RICHARD/AU
L15 27 S ALEWOOD PAUL/AU
L16 1 S SHARPE IAIN/AU
L17 0 S (L14 OR L15 OR L16) AND L1

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	104.84	105.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 09:15:16 ON 29 AUG 2003